

Supplementary Material

Poster Title:

Mapping to EQ-5D Utility in Knee Osteoarthritis: A Comparative Evaluation of WOMAC and SF-36 Algorithms in the STEP 9 Trial

Authors:

Vagia Daki¹; Karthik Ramakrishnan²; Konstantinos Soulanis¹; Ines Guerra³; Theodora Oikonomidi¹; Inger Smith⁴

Affiliations:

¹IQVIA, Athens, Greece; ²Novo Nordisk A/S, Bengaluru, India; ³IQVIA, London, United Kingdom; ⁴White Box Health Economics Ltd, Brighton & Hove, UK

This trial was sponsored by Novo Nordisk and is registered with ClinicalTrials.gov (NCT05064735).

Conference:

ISPOR Europe 2025, Glasgow, November 10

Presented at:

ISPOR Europe 2025, Glasgow, November 10

Contents

Supplementary Tables.....	3
Supplementary Figures	4
Extended List of References	5

Supplementary Tables


Table 1. Sample size and body-mass index across the WOMAC and SF-36 to EQ-5D mapping studies

Study	Sample size	BMI (Mean)
WOMAC Mapping		
Wailoo 2014	1,768	29.7
Xie 2010	258	28.2
Barton 2008	259	28.0
Ayala 2021	758	NR
Bilbao 2020	758	NR
Price 2019	339	32.6
SF-36 Mapping		
Rowen 2009	23,179	NR
Ara-Brazier 2008	6,350	NR
Maund 2012	113	NR
Kim 2014	2,211	NR

Abbreviations: BMI, body-mass index; EQ-5D, EuroQol-5 Dimension; NR, Not reported; SF-36, Short Form (36) Health Survey; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

Supplementary Figures

Figure 1. Distribution of SF-36 scores across STEP 9 and the identified SF-36 mapping studies



Extended List of References

1. Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelvesæth J, Hoffmann Morville T, Koroleva A, Skov Neergaard J, Vélez Sánchez P, Wharton S, Wizert A. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. *New England Journal of Medicine*. 2024 Oct 31;391(17):1573-83.
2. Dakin H, Abel, L, Burns R, Koleva-Kolarova R, Yang Y, 2023. HERC database of mapping studies, Version 9.0 (Last updated: 1st December 2023). <https://doi.org/10.5287/ora-avomzqyvb>. Available at: <http://www.herc.ox.ac.uk/downloads/herc-database-of-mapping-studies>.
3. Wailoo A, Hernandez Alava M, Pudney S. Mapping to estimate health state utility values. Technical Support Document 22. Decision Support Unit, SchARR, University of Sheffield; 2023. Available from: <https://www.sheffield.ac.uk/media/42422/download>.
4. Ayala A, Forjaz MJ, Ramallo-Fariña Y, Martín-Fernández J, García-Pérez L, Bilbao A. Response mapping methods to estimate the EQ-5D-5L from the western Ontario McMaster universities osteoarthritis in patients with hip or knee osteoarthritis. *Value in Health*. 2021 Jun 1;24(6):874-83.
5. Bilbao A, Martín-Fernández J, García-Pérez L, Arenaza JC, Ariza-Cardiel G, Ramallo-Fariña Y, Ansola L. Mapping WOMAC onto the EQ-5D-5L utility index in patients with hip or knee osteoarthritis. *Value in Health*. 2020 Mar 1;23(3):379-87.
6. Price A, Smith J, Dakin H, Kang S, Eibich P, Cook J, Gray A, Harris K, Middleton R, Gibbons E, Benedetto E. The Arthroplasty Candidacy Help Engine tool to select candidates for hip and knee replacement surgery: development and economic modelling. *Health Technology Assessment (Winchester, England)*. 2019 Jun;23(32):1.
7. Xie, F., Pullenayegum, E. M., Li, S. C., Hopkins, R., Thumboo, J., & Lo, N. N. (2010). Use of a disease-specific instrument in economic evaluations: mapping WOMAC onto the EQ-5D utility index. *Value in Health*, 13(8), 873-878.
8. Barton, G. R., Sach, T. H., Jenkinson, C., Avery, A. J., Doherty, M., & Muir, K. R. (2008). Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores?. *Health and quality of life outcomes*, 6, 1-11.
9. Wailoo, A., Hernandez Alava, M., & Escobar Martinez, A. (2014). Modelling the relationship between the WOMAC osteoarthritis index and EQ-5D. *Health and quality of life outcomes*, 12, 1-6.

10. Rowen D, Brazier J, Roberts J. Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?. *Health and quality of life outcomes*. 2009 Dec;7:1-9.
11. Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36-dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). *Value in Health*. 2008 Dec;11(7):1131-43.
12. Maund E, Craig D, Suekarran S, Neilson AR, Wright K, Brealey S, Dennis L, Goodchild L, Hanchard N, Rangan A, Richardson G. Management of frozen shoulder: a systematic review and cost-effectiveness analysis.
13. Kim SH, Kim SO, Lee SI, Jo MW. Deriving a mapping algorithm for converting SF-36 scores to EQ-5D utility score in a Korean population. *Health and quality of life outcomes*. 2014 Dec;12:1-0.
14. Forestier, R., Debiais, F., Michel, N., Schueller, R., & Juhel, C. (2025). The effectiveness of a 3-week spa therapy on the 6-month mobility and functional ability of patients with knee osteoarthritis: the ANGELLO randomized controlled trial. *International Journal of Biometeorology*, 1-10.
15. Ciaffi, J., Mancarella, L., Pederzani, G., Lisi, L., Brusi, V., Pignatti, F., ... & Ursini, F. (2024). Efficacy, safety, and tolerability of a very low-calorie ketogenic diet in women with obesity and symptomatic knee osteoarthritis: a pilot interventional study. *Nutrients*, 16(19), 3236.
16. Ateş, Y., Akdoğan, M., & Atilla, H. A. (2021). Which knee replacement do the patients forget? Unicondylar or total knee arthroplasty. *Acta Orthop Traumatol Turc*, 55(5), 417-421.

Additional recommended references

1. National Institute for Health and Care Excellence (NICE). *Technology Appraisal Guidance [TA477]*. London: NICE; 2017.
2. EuroQol Group. *EQ-5D User Guide*. Rotterdam: EuroQol Research Foundation; 2018.
3. ISPOR Task Force for Good Research Practices. *Mapping to estimate health-state utility from non-preference-based outcome measures: ISPOR Good Practices for Outcomes Research Task Force Report*. *Value Health*. 2017;20(1):18–27.